Shen, R., Cao, W., Wang, L., Sheng, L., Zhang, Y., Wu, W., . . . Zhao, W. Response‐adapted zanubrutinib and tislelizumab as a potential strategy to enhance CD19 CAR T‐cell therapy in relapsed/refractory large B‐cell lymphoma: A retrospective observational study. Wiley.
Chicago Style (17th ed.) CitationShen, Rong, et al. Response‐adapted Zanubrutinib and Tislelizumab as a Potential Strategy to Enhance CD19 CAR T‐cell Therapy in Relapsed/refractory Large B‐cell Lymphoma: A Retrospective Observational Study. Wiley.
MLA (9th ed.) CitationShen, Rong, et al. Response‐adapted Zanubrutinib and Tislelizumab as a Potential Strategy to Enhance CD19 CAR T‐cell Therapy in Relapsed/refractory Large B‐cell Lymphoma: A Retrospective Observational Study. Wiley.
Warning: These citations may not always be 100% accurate.